Short-term relaxin treatment promotes endothelium-related vasodilation by upregulating eNOS, COX2, and prostacyclin receptor expression and reverses hypertension-induced vascular dysfunction through interactions with endothelium-derived contracting factors by restoring endothelium-derived PGI2 vasodilator pathways. This evidence concerns the gene NOS3 and Hypertension.